Drug Repositioning: The Business Case and Current Strategies to Repurpose Shelved Candidates and Marketed Drugs

Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs

Volumn , Issue , 2012, Pages 7-32

  Arrowsmith, John ^a   Harrison, Richard ^b  

^a THOMSON REUTERS   (United Kingdom)

^b Thomson Reuters   (United States)

Author keywords

Pharmaceutical R D failings, drug repositioning strategies; Repurpose shelved candidates, marketed drugs; Repurposing existing drugs

Indexed keywords

EID: 84886466322     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118274408.ch1     Document Type: Chapter

References (43)

1. Ashburn, T.T., Thor, K.B. (2004). Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews. Drug Discovery, 3, 673.
2. Tobinick, E.L. (2009). The value of drug repositioning in the current pharmaceutical market. Drug News & Perspectives, 22, 119.
3. Campas, C. (2009). Drug repositioning summit: Finding new routes to success. Drug News & Perspectives, 22, 126.
4. Kaitin, K.I., DiMasi, J.A. (2011). Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000 - 2009. Clinical Pharmacology and Therapeutics, 89, 183.
5. DiMasi, J.A., Feldman, L., Seckler, A., Wilson, A. (2010). Trends in risks associated with new drug development: Success rates for investigational drugs. Clinical Pharmacology and Therapeutics, 87, 272.
6. CMR International 2010 Global R & D Performance Metrics Programme. http:// cmr.thomsonreuters.com/services/programs/randd/.
7. CMR International 2011 Pharmaceutical Fact Book. http://cmr.thomsonreuters.com/.
8. IMS Institute for Healthcare Informatics (2011) The Global Use of Medicines: Outlook through 2015; May 2011
9. EvaluatePharma World preview 2016 " Beyond the Patent Cliff " (June, 2011)
10. Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nature Reviews. Drug Discovery, 8, 959.
11. Food and Drug Administration (FDA) Drug and Biologic Approval Reports. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ default.htm
12. Arrowsmith, J. (2011). Trial watch phase III and submission failures: 2007 - 2010. Nature Reviews. Drug Discovery, 10 (1), 87.
13. D'Agostino, R.B. (2011). Changing end points in breast - cancer drug approval - The avastin story. The New England journal of medicine, 365, e2.
14. Food and Drug Administration (FDA) Drug and Biologic Approval Reports. http:// www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071590.pdf
15. Jack, A. (2010). Big pharma aims for reinvention. The Financial Times, October 2, 2010.
16. Food and Drug Administration (FDA) Drug and Biologic Approval Reports. http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ Pharmacogenetics/ucm085575.pdf
17. Food and Drug Administration (FDA) Drug and Biologic Approval Reports. http:// www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ucm215089.htm
18. Food and Drug Administration (FDA) Drug and Biologic Approval Reports. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/ WC500003517.pdf
19. Jarvis, L. (2006). Teaching an old drug new tricks. Chemical and Engineering News, 84, 52.
20. Bhattacharya, S., Coghlan, A. (2006). One drug, six men, disaster. New scientist (1971), Mar 25 - 31; 189 (2544), 10 - 11.
21. Matthews, S.J., McCoy, C. (2003). Thalidomide: A review of approved and investigational uses. Clinical Therapeutics, 25, 342.
22. Bernard, P., Dufresne - Favetta, C., Favetta, P., Do, Q.T., Himbert, F., Zubrzycki, S., Scior, T., Lugnier, C.P. (2008). Application of drug repositioning strategy to TOFISOPAM. Current Medicinal Chemistry, 15, 3196.
23. Bisson, W.H., Cheltsov, A.V., Bruey-Sedano, N., Lin, B., Chen, J., Goldberger, N., May, L.T., Christopoulos, A., Dalton, J.T., Sexton, P.M., Zhang, X.K., Abagyan, R. (2007). Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proceedings of the National Academy of Sciences of the United States of America, 104, 11927.
24. Dubus, E., Ijjaali, I., Barberan, O., Petitet, F. (2009). Drug repositioning using in silico compound profiling. Future Medicinal Chemistry, 1, 1723.
25. Ren, J.Y., Xie, L., Li, W.W., Bourne, P.E. (2010). SMAP - WS: A parallel web service for structural proteome - wide ligand - binding site comparison. Nucleic Acids Research, 38, W441.
26. Subramanian, G., Sud, M. (2010). Computational modeling of kinase inhibitor selectivity. ACS Medicinal Chemistry Letters, 1, 395.
27. Bhattacharya, A., Mishra, L.C., Bhasin, V.K. (2008). In vitro activity of artemisinin in combination with clotrimazole or heat - treated amphotericin B against Plasmodium falciparum. The American Journal of Tropical Medicine and Hygiene, 78, 721.
28. Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., Di Bernardo, D. (2010). Discovery of drug mode of action and drug repositioning from transcriptional responses. Proceedings of the National Academy of Sciences of the United States of America, 107, 14621.
29. Kinnings, S.L., Liu, N., Buchmeier, N., Tonge, P.J., Xie, L., Bourne, P.E. (2009). Drug discovery using chemical systems biology: Repositioning the safe medicine Comtan to treat multi - drug and extensively drug resistant tuberculosis. PLoS Computational Biology, 5, e1000423.
30. Tartaglia, L.A. (2006). Complementary new approaches enable repositioning of failed drug candidates. Expert Opinion on Investigational Drugs, 15, 1295.
31. Clouser, C.L., Patterson, S.E., Mansky, L.M. (2010). Exploiting drug repositioning for discovery of a novel HIV combination therapy. Journal of Virology, 84, 9301.
32. Gills, J.J., LoPiccolo, J., Dennis, P.A. (2008). Nelfinavir, a new anti - cancer drug with pleiotropic effects and many paths to autophagy. Autophagy, 4, 107.
33. Saporito, M.S. et al. (2007). CINF 14 - MLR - 1023: A drug candidate for type II diabetes with a novel molecular target discovered by using an in vivo drug repositioning approach. Abstracts of Papers of the American Chemical Society, 234, 14.
34. Ghofrani, H.A., Osterloh, I.H., Grimminger, F. (2006). Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Reviews. Drug Discovery, 5 (8), 689 - 702.
35. U.S. National Library of Medicine. http://ghr.nlm.nih.gov/condition/muckle - wells -syndrome
36. Lachmann, H.J., Kone - Paut, I., Kuemmerle - Deschner, J.B., Leslie, K.S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., Hawkins, P.N.; Canakinumab in CAPS Study Group (2009). Use of canakinumab in the cryopyrin - associated periodic syndrome. The New England Journal of Medicine, 360 (23), 2416 - 2425.
37. Menendez, J.A., Lupu, R. (2007). Targeting human epidermal growth factor receptor 2: It is time to kill kinase death human epidermal growth factor receptor 3. Journal of Clinical Oncology, 25 (17), 2496 - 2498.
38. Roche. http://www.roche.com/med - cor - 2010 - 12 - 10
39. Fabro, S., Smith, R.L., Williams, R.T. (1967). Toxicity and teratogenicity of optical isomers of thalidomide. Nature, 215 (5098), 296.
40. Ng, S.S., Brown, M., Figg, W.D. (2002). Thalidomide, an antiangiogenic agent with clinical activity in cancer. Biomed Pharmacother, 56 (4), 194 - 199.
41. DiPersio, J.F., Uy, G.L., Yasothan, U., Kirkpatrick, P. (2009). Plerixafor. Nature Reviews. Drug Discovery, 8, 105.
42. Drugs.com. http://www.drugs.com/new - indications.html
43. Food and Drug Administration (FDA) Drug and Biologic Approval Reports. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm